GUD Knight Therapeutics

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference

MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET. A copy of the investor presentation will be available at .

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or . 

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law. 

CONTACT INFORMATION:

Investor Contact:  
Knight Therapeutics Inc.  
Samira Sakhia Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. +598.2626.2344
F: 514.481.4116  
Email:  Email: 
Website:  Website: 



EN
04/08/2022

Underlying

GUDKnight Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Knight Therapeutics

 PRESS RELEASE
Free
GUD Knight Therapeu...

Knight Therapeutics Announces Health Canada Approval for WYNZORA® to T...

Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA®, a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), indicated for the topical treatment of psoriasis vulgaris in adults and adolescents aged 12-17 years for up to 8 weeks.1 Knight obtained the Canadian rights to WYNZORA® through ...

December 18, 2025 1 EN
 PRESS RELEASE
Free
GUD Knight Therapeu...

Thérapeutique Knight annonce l’obtention de l’autorisation de Santé Ca...

Thérapeutique Knight annonce l’obtention de l’autorisation de Santé Canada pour WYNZORA® pour le traitement du psoriasis vulgaris MONTRÉAL, 18 déc. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc., (TSX : GUD) (« Knight »), société pharmaceutique panaméricaine (hors États-Unis) spécialisée, a annoncé aujourd’hui que Santé Canada a approuvé WYNZORA®, une crème blanche uniforme contenant 0,05 mg/g de calcipotriol (CAL) et 0,5 mg/g de dipropionate de bétaméthasone (BDP), indiquée pour le traitement topique du psoriasis vulgaris chez les adultes et les adolescents de 12 à 17 ans pour une du...

December 18, 2025 1 EN
 PRESS RELEASE
Free
GUD Knight Therapeu...

Knight Therapeutics Reports Third Quarter 2025 Results

Knight Therapeutics Reports Third Quarter 2025 Results Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance MONTREAL, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q3-25 Highligh...

November 6, 2025 1 EN
 PRESS RELEASE
Free
GUD Knight Therapeu...

Thérapeutique Knight déclare ses résultats du troisième trimestre de 2...

Thérapeutique Knight déclare ses résultats du troisième trimestre de 2025 Niveau record trimestriel de produits des activités ordinaires, de BAIIA ajusté1 et de BAIIA ajusté par action1 Prévisions financières révisées à la hausse pour 2025 MONTRÉAL, 06 nov. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), une société pharmaceutique spécialisée panaméricaine (à l’exclusion des É.-U.), a annoncé aujourd’hui ses résultats financiers pour le troisième trimestre clos le 30 septembre 2025. Tous les montants sont exprimés en milliers de dollars cana...

November 6, 2025 1 EN
 PRESS RELEASE
Free
GUD Knight Therapeu...

Knight Announces Closing of US$100 Million Revolving Credit Facility

Knight Announces Closing of US$100 Million Revolving Credit Facility MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has closed the syndication of its US$100 million secured revolving credit facility (“the Credit Facility”). On June 17, 2025, Knight had announced that it had closed a US$50 Million revolving credit facility with National Bank of Canada (“NBC”) and initiated a syndication process to increase the size of the facility. As part of the...

October 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch